WuXi XDC Cayman Anticipates 260% Surge in Net Profit for 2024
MT Newswires Live01-15
WuXi XDC Cayman (HKG:2268) expects a net profit of 260% higher in 2024 than in 2023, a Wednesday Hong Kong bourse filing said.
The company also expects its revenue for the reporting year to jump 85% compared with the year prior.
The antibody-drug conjugates company attributed the surge in its expected net profit and revenue for the reporting period to steady downstream demand from the fast growth of antibody-drug conjugate and the expanded bio-conjugate industry.
The group also attributed the higher gains for 2024 to its competitive strength and increased profit margins for the reporting period resulting from improved production efficiency.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
